Filtered By:
Source: Annals of Allergy, Asthma and Immunology
Condition: Hay Fever
This page shows you your search results in order of date.
Order by Relevance | Date
Total 272 results found since Jan 2013.
Causes and implications of increasing costs of prescription medications for allergists
Affecting 10% to 50% of the population, allergic rhinitis (AR) is 1 of the world's most prevalent chronic illnesses, generating a significant burden to society through treatment costs and quality-of-life decrements.1 In the United States, the annual cost of AR is estimated to range from $2 to $5 billion (2003 estimate).1 Allergen immunotherapy is an option for treating AR, but pharmaceutical medications remain the cornerstone of management. Unfortunately, as detailed in the thought-provoking article by Mi et al,2 the cost of many of these rhinologic medications has been increasing, adding more financial burden to patients with AR.
Source: Annals of Allergy, Asthma and Immunology - September 1, 2023 Category: Allergy & Immunology Authors: Di Sun, Christopher D. Codispoti Tags: Editorial Source Type: research
Diabetes Mellitus and Bone Mineral Density on Fracture Risk in Allergic Rhinitis and Asthma Patients
Asthma (AS) and allergic rhinitis (AR) are the most common allergic diseases, affecting more than 20% of the population.1, 2 In Taiwan, the prevalence rates of asthma and AR were 11.9% and 26.3%, respectively.3 Almost 50% of patients with allergic disease had AR and AS concomitantly.3 Asthma patients have even greater rate of fracture and osteoporosis.1,4 However, there are inconsistencies and contradictions regarding the possible harmful effects of inhaled corticosteroid treatment, such as decreased bone mineral density (BMD) and enhanced fracture risk in asthma patients, based on some review studies.
Source: Annals of Allergy, Asthma and Immunology - August 7, 2023 Category: Allergy & Immunology Authors: Chun-Sheng Hsu, Yi-Ming Chen, Chiann-Yi Hsu, Ya-Lian Deng, Yu-Wen Chu Tags: Letters Source Type: research
Diabetes mellitus and bone mineral density on fracture risk in patients with allergic rhinitis and asthma
Asthma (AS) and allergic rhinitis (AR) are the most common allergic diseases, affecting more than 20% of the population.1,2 In Taiwan, the prevalence rates of AS and AR were 11.9% and 26.3%, respectively.3 Almost 50% of patients with allergic disease had AR and AS concomitantly.3 Patients with AS have even greater rate of fracture and osteoporosis.1,4 However, there are inconsistencies and contradictions regarding the possible harmful effects of inhaled corticosteroid treatment, such as decreased bone mineral density (BMD) and enhanced fracture risk in patients with AS, based on some review studies.
Source: Annals of Allergy, Asthma and Immunology - August 7, 2023 Category: Allergy & Immunology Authors: Chun-Sheng Hsu, Yi-Ming Chen, Chiann-Yi Hsu, Ya-Lian Deng, Yu-Wen Chu Tags: Letters Source Type: research
Insights into mechanisms of immunotherapy circa 1943: “What has been will be again”
Commentary on: “The presence of thermostable inhibiting factor in the sera of patients treated for hay fever by injections of pollen extract.” Annals of Allergy. May-June, 1944, pp. 207-229. Ethan Allen Brown, MD, and Captain Eugene M Holden, MD.1
Source: Annals of Allergy, Asthma and Immunology - August 1, 2023 Category: Allergy & Immunology Authors: Larry Borish Tags: Special Perspective Source Type: research
Evidence-based use of antihistamines for treatment of allergic conditions
Available since the 1940s, H1-antihistamines are mainstay treatments for allergic conditions such as allergic rhinitis and urticaria. They function as inverse agonists that bind to the H1 receptor to inhibit histamine-induced inflammation. The older, first-generation drugs are no longer recommended for patient use due to their well documented negative side effect profile. Evidence has been accumulating to support a newer generation of H1-antihistamines in oral and intranasal formulations, including in combination with intranasal corticosteroids.
Source: Annals of Allergy, Asthma and Immunology - July 28, 2023 Category: Allergy & Immunology Authors: Sophia Linton, Lubnaa Hossenbaccus, Anne K. Ellis Tags: CME Reviews Source Type: research
Eosinophilic granulomatosis with polyangiitis presenting as aspirin –exacerbated respiratory disease
Eosinophilic granulomatosis with polyangiitis (EGPA) is a multisystem disorder causing granulomatous inflammation of both small- and medium-sized arteries with hypereosinophilia and eosinophilic systemic tissue infiltration. EGPA can involve the lungs, sinuses, kidneys, heart, nervous system, intestinal tract, or skin.1 Onset is usually between the third and fifth decades of life with the following 3 stages: the prodromal stage with atopic diseases, that is, allergic rhinitis and asthma; the eosinophilic stage where organs become infiltrated with eosinophils and peripheral blood hypereosinophilia; and the final vasculitic ...
Source: Annals of Allergy, Asthma and Immunology - July 22, 2023 Category: Allergy & Immunology Authors: Sabrina D. Herzberg, Alyssa M. Bosso, Neel R. Sangal, John V. Bosso Tags: Letters Source Type: research
Disparity Between Mold Immunotherapy Dosing and Practice Parameter Recommendations in a Large Healthcare Setting.
Molds are ubiquitous, eukaryotic micro-organisms that reproduce from spores and belong to the Fungi kingdom. They have been implicated in a number of hypersensitivity disorders including asthma, allergic rhinitis, hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis, allergic fungal rhinosinusitis, and atopic dermatitis.1 Allergen immunotherapy (AIT) represents a potentially disease modifying therapy for individuals sensitized to mold, and its efficacy has been established for the treatment of allergic rhinitis and allergic asthma.
Source: Annals of Allergy, Asthma and Immunology - April 22, 2023 Category: Allergy & Immunology Authors: Christopher V. Macomb, Christopher S. Chavarria, Michael R. Nelson, Satyen M. Gada, David J. Schwartz Tags: Letters Source Type: research
Randomized Double Blind Pilot Study of Universal, Species Abundant, Multi-Allergen Subcutaneous Immunotherapy for Moderate-Severe Allergic Rhinitis
Allergic rhinitis affects approximately 10-20% of people living in industrialized nations leading to significant morbidity and large health care expenditures. Individualized high-dose, single species allergen immunotherapy has been shown to be effective in treating allergic rhinitis but can be associated with significant risks including anaphylaxis. Few studies have examined the safety and efficacy of universal low-dose multi-allergen immunotherapy.
Source: Annals of Allergy, Asthma and Immunology - March 27, 2023 Category: Allergy & Immunology Authors: Jody Tversky, Pooja Patel, Mudiaga Sowho, Rakesh Natarajan, Tae Chung, Andrew Whelton, Antoine Azar Source Type: research
Randomized double-blind pilot study of universal, species abundant, multiallergen subcutaneous immunotherapy for moderate-severe allergic rhinitis
Allergic rhinitis affects approximately 10% to 20% of people living in industrialized nations leading to significant morbidity and large health care expenditures. Individualized high-dose, single-species allergen immunotherapy has been found to be effective in treating allergic rhinitis but can be associated with significant risks including anaphylaxis. Few studies have evaluated the safety and efficacy of universal low-dose multiallergen immunotherapy (MAIT).
Source: Annals of Allergy, Asthma and Immunology - March 27, 2023 Category: Allergy & Immunology Authors: Jody Tversky, Pooja Patel, Mudiaga Sowho, Rakesh Natarajan, Tae Chung, Andrew Whelton, Antoine Azar Tags: Original Article Source Type: research
Sublingual immunotherapy (SLIT) for house dust mite — when to take a break?
Allergic conditions such as allergic rhinitis1 have been increasing in recent years, leading to the development of many forms of immunotherapy.2 One such recent development is the standardized quality house dust mite (HDM) allergen extract tablets (Acarizax), which have been proven a safe and effective management option for sublingual allergy immunotherapy (SLIT) in adults with confirmed HDM-induced allergic rhinitis or allergic asthma.3 Acarizax is generally well tolerated by adults with allergic rhinitis;4 however, some experience mild-to-moderate allergic reactions in the mouth that generally subside within a few days.
Source: Annals of Allergy, Asthma and Immunology - March 14, 2023 Category: Allergy & Immunology Authors: Aoife Gallagher, Juan Trujillo Tags: Letters Source Type: research
Sublingual immunotherapy (SLIT) for house dust mite – when to take a break? An unusual reaction to SLIT post-vaccinations
Allergic conditions such as allergic rhinitis1, are on the rise in recent years leading to the development of many forms of immunotherapy2. One such recent development is the standardized quality (SQ) house dust mite (HDM) allergen extract tablets (Acarizax), which have been proven a safe and effective management option for sublingual allergy immunotherapy (SLIT) in adults with confirmed HDM-induced allergic rhinitis or allergic asthma3. Acarizax is generally well tolerated by adults with allergic rhinitis4, however some experience mild to moderate allergic reactions in the mouth, which generally subside within a few days.
Source: Annals of Allergy, Asthma and Immunology - March 14, 2023 Category: Allergy & Immunology Authors: A. Gallagher, J. Trujillo Source Type: research
House Dust Mite Sublingual Immunotherapy Tablet Safety in Adolescents with Allergic Rhinoconjunctivitis: Clinical Trial Results
: The HDM sublingual immunotherapy (SLIT)-tablet is a treatment option for allergic rhinitis with/without conjunctivitis (AR/C) approved in adults worldwide and in adolescents in some countries.
Source: Annals of Allergy, Asthma and Immunology - March 14, 2023 Category: Allergy & Immunology Authors: Andreas Horn, David I. Bernstein, Kimihiro Okubo, Terrie Dalgaard, Ole Hels, Helle Frob øse Sørensen, Marianne Henriksen, Ryuji Azuma, Jan Mikler, Hendrik Nolte Tags: Original Article Source Type: research
From the Pages of AllergyWatch
For this edition of From the Pages of AllergyWatch, I've chosen articles from the Nov-Dec AllergyWatch. The first article, with comments from Dr. Hernandez-Trujillo, investigates the impact of allergic rhinitis on sleep problems in children. The next article, with comments from Dr. Joshi, presents a new symptom-based tool that can predict the risk for the child to develop asthma. The third article, with comments from Dr. Knox, reports data using SABA/ICS combo as a rescue medication for asthma.
Source: Annals of Allergy, Asthma and Immunology - December 14, 2022 Category: Allergy & Immunology Authors: Stanley Fineman, Vivian Hernandez-Trujillo, Shyam Joshi, Samantha Knox Source Type: research
Vanishing vitiligo? dupilumab and aeroallergen immunotherapy improve longstanding vitiligo
We present a case of a patient with substantial, incremental improvement in vitiligo after starting dupilumab and AIT for severe atopic dermatitis, asthma, and allergic rhinitis.Case Presentation: The patient is a 55 year-old female with a history of asthma, atopic dermatitis, allergic rhinitis, and vitiligo. Aeroallergen immunotherapy to multiple seasonal and perennial allergens was started with significant improvement in her asthma and rhinitis symptoms.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2022 Category: Allergy & Immunology Authors: M. Miller, M. Kessenich, C. Mikita Tags: M335 Source Type: research
Dupilamab for post-viral smell loss in allergic rhinitis and chronic rhinosinusitis without nasal polyposis
Evaluate effectiveness of dupilamab for post-viral smell loss with allergic rhinitis (AR), and chronic rhinosinusitis without nasal polyposis (CRSsNP).
Source: Annals of Allergy, Asthma and Immunology - November 1, 2022 Category: Allergy & Immunology Authors: E. Fernandez, M. Goldstein Tags: Rhinitis, Other Upper Airway Disorders M320 Source Type: research
